Tools   Select Another Resource Report Type

https://www.nimhgenetics.org/

Collaborative venture between the National Institute of Mental Health (NIMH) and several academic institutions. Repository facilitates psychiatric genetic research by providing patient and control samples and phenotypic data for wide-range of mental disorders and Stem Cells.Stores biosamples, genetic, pedigree and clinical data collected in designated NIMH-funded human subject studies. RGR database likewise links to other repositories holding data from same subjects, including dbGAP, GEO and NDAR. Allows to access these data and biospecimens (e.g., lymphoblastoid cell lines, induced pluripotent cell lines, fibroblasts) and further expand genetic and molecular characterization of patient populations with severe mental illness.

Proper citation: NIMH Repository and Genomics Resources (RRID:SCR_006698) Copy   

•   Source: SciCrunch Registry

http://roslincells.com/

Organization that supplies undifferentiated, clinical grade, human pluripotent stem cell lines to the life science community, and works with academic, clinical and commercial colleagues to enable and facilitate the use of these high grade cells in the development of new reagents, drugs and cellular therapeutics. They also seek to drive the economic development of the stem cell sector in Scotland. Their products can act as a valuable tool in supporting clients' drug discovery, development and clinical research programmes.

Proper citation: Roslin Cells (RRID:SCR_003857) Copy   

•   Source: SciCrunch Registry

http://www.endocells.fr/?lang=en

This resource no longer in service. Documented on August 12, 2021. French biotech company dedicated to human endocrine cell line production with a first focus on human pancreatic beta cell. Other cell types are being prepared like glucagon cells. The material will be powerful tools for drug discovery, toxicology and cell replacement therapy. Achievements to date * Generated tumoral and non-tumoral human beta cell lines which closely resemble human primary pancreatic beta cells (using technologies which have been first developed and validated using immortalized rat beta cell lines). World first. * Established a robust technology platform which will be used to develop other human endocrine cell lines.

Proper citation: Endocells (RRID:SCR_004067) Copy   

•   Source: SciCrunch Registry

http://www.osiris.com/

Stem cell company focused on developing and marketing products to treat medical conditions in the inflammatory, autoimmune, orthopedic and cardiovascular areas. Now part of Smith and Nephew.

Proper citation: Osiris Therapeutics (RRID:SCR_004233) Copy   

•   Source: SciCrunch Registry

http://www.origene.com/

A research tool company focused on the creation of the largest commercial collection of full-length human cDNAs in a standard expression vector. The availability of the complete human genome sequence and the subsequent development of genome-based tools have enabled the identification of relevant drug targets through system biology approaches. OriGene''s vision is to prepare comprehensive, genome wide research tools and technology platforms to enable scientists to study complete biological pathways, thus enabling a better understanding of disease mechanisms including cancer and stem cell research. OriGene Technologies uses high-throughput, genome wide approach to develop products for pharmaceutical, biotechnology, and academic research. Their flagship product is the cDNA clone collection, a searchable gene bank of over 30,000 human full-length TrueClone cDNA collection and over 25,000 TrueORF cDNA clones. From their TrueORF cDNA clones, they have developed the largest offering of full length human proteins expressed in mammalian cells, ideal for functional studies. Their TrueMAB project develops mouse monoclonal antibodies against protein antigens with the goal to develop protein assays for every human protein. They also offer complete molecular biology services from codon optimization, gene synthesis, protein expression and assay development. In addition, they offer unique gene expression products such as TissueScan cancer tissue qPCR arrays and tissue biorepository for biomarker discovery and validation.

Proper citation: OriGene (RRID:SCR_008985) Copy   

•   Source: SciCrunch Registry

http://www.bari2d.org/

A multicenter randomized clinical trial that aims to determine the best therapies for people with type 2 diabetes and moderately severe cardiovascular disease. 2368 participants were randomized at 49 sites in 6 countries. All subjects were given intensive medical therapy to control cholesterol and blood pressure and given counseling, if needed, to quit smoking and to lose weight. Beyond that, they compared whether prompt revascularization, either bypass surgery or angioplasty, e.g. stents, was more effective than medical therapy alone. At the same time, they also looked at which of two diabetes treatment strategies resulted in better outcomes����??insulin-providing versus insulin-sensitizing - that is, increasing the amount of insulin or making the insulin work better. Only patients with known type 2 diabetes and heart disease that could be treated appropriately with a revascularization OR medical therapy alone were eligible for the trial. Patients entered the study between January 2001 ����?? March 2005 and were followed for an average of five years. When a patient entered the study, physicians first decided whether that patient should receive stenting or bypass surgery. The patient then received their randomization assignment. All patients were treated in BARI 2D for both their diabetes and heart disease, as well as other risk factors that might effect those diseases, regardless of which group they were in. Diabetes-specific complications including retinopathy, nephropathy, neuropathy, and peripheral vascular disease were monitored regularly. Tests, blood samples, urine samples, and treatment cost data were obtained periodically through the trial and examined by experts at 7 central laboratories and other research partners. Experts on risk factors routinely oversaw treatments of all patients at 4 central management centers. A panel of independent experts reviewed data every six months to make sure that all patients were receiving safe care.

Proper citation: BARI 2D (RRID:SCR_001496) Copy   

•   Source: SciCrunch Registry

http://www.atcc.org/

Global nonprofit biological resource center (BRC) and research organization that provides biological products, technical services and educational programs to private industry, government and academic organizations. Its mission is to acquire, authenticate, preserve, develop and distribute biological materials, information, technology, intellectual property and standards for the advancement and application of scientific knowledge. The primary purpose of ATCC is to use its resources and experience as a BRC to become the world leader in standard biological reference materials management, intellectual property resource management and translational research as applied to biomaterial development, standardization and certification. ATCC characterizes cell lines, bacteria, viruses, fungi and protozoa, as well as develops and evaluates assays and techniques for validating research resources and preserving and distributing biological materials to the public and private sector research communities.

Proper citation: ATCC (RRID:SCR_001672) Copy   

•   Source: SciCrunch Registry

http://www.jax.org/index.html

An independent, nonprofit organization focused on mammalian genetics research to advance human health. Their mission is to discover the genetic basis for preventing, treating, and curing human disease, and to enable research for the global biomedical community. Jackson Laboratory breeds and manages colonies of mice as resources for other research institutions and laboratories, along with providing software and techniques. Jackson Lab also conducts genetic research and provides educational material for various educational levels.

Proper citation: Jackson Laboratory (RRID:SCR_004633) Copy   

•   Source: SciCrunch Registry

http://www.hema-quebec.qc.ca/index.en.html

Hema-Quebec''s mission is to efficiently provide adequate quantities of safe, optimal blood components, substitutes, human tissues and cord blood to meet the needs of all Quebecers; provide and develop expertise along with specialized and innovative services and products in the fields of transfusion medicine and human tissue transplantation. Hema-Quebec is driven by the commitment, support and recognition of its employees as well as the trust of its partners to remain the standard of quality and innovation with respect to the safe procurement of blood products, human tissues and stem cells.

Proper citation: Hema-Quebec (RRID:SCR_004700) Copy   

•   Source: SciCrunch Registry

http://www.giftofhope.org/

Gift of Hope Organ & Tissue Donor Network is proud to serve as the federally designated not-for-profit agency that coordinates organ and tissue donation and supports families of donors in the northern three-quarters of Illinois and northwest Indiana. Since our inception in 1986, we have coordinated donations that have saved the lives of 17,000 organ transplant recipients and helped hundreds of thousands of other patients receive needed tissue transplants. As one of 58 organ procurement organizations (OPOs) that make up the nation''s organ donation system, we work with 179 hospitals in our donation service area. In managing the recovery, care and transportation of donated organs to transplant patients, we work closely with Illinois'' nine transplant centers, which operate 32 transplant programs. We also work with other transplant centers and other OPOs through the United Network for Organ Sharing (UNOS) to provide lifesaving organs for patients awaiting them. UNOS is the federally mandated registration center for organ transplant candidates in the United States. UNOS'' computer-based system matches donated organs with patients in need, in accordance with strict federal guidelines intended to ensure equitable distribution.

Proper citation: Gift of Hope Organ and Tissue Donor Network (RRID:SCR_004968) Copy   

•   Source: SciCrunch Registry

http://www.allosource.org/

AlloSource is a non-profit organization founded in 1994 on a promise to honor and respect the gift of donation by responsibly developing, processing and distributing life-saving and life-enhancing allografts for our communities. Today, each of our 300 employees continues to fulfill this promise through multi-shift, 360-day processing to the highest quality and service standards. We strive to be the tissue network patients and the world''s most respected transplant teams ask for by name. This is accomplished by understanding the needs of our doctors and by providing the best tissue for our recipients. We offer more than 200 standard and customized precision allograft products, and act as a trusted and knowledgeable partner to the medical community, all with the intention of maximizing medical impact. In 1995, Allosource evolved from a local tissue bank in Denver, Colorado into a national organization serving communities around the country. Today, AlloSource is one of the largest, most respected tissue banks in the United States. Through our growth we''ve remained committed to the wishes of donor families, the needs of our surgeon customers, and the hopes of our patient recipients. Our promise of doing more with life reflects our unwavering focus on integrity, quality, safety, and respect today, and into the future.

Proper citation: AlloSource (RRID:SCR_010683) Copy   

•   Source: SciCrunch Registry

http://tulane.edu/som/regenmed/services/index.cfm

The Stem Cell Research and Regenerative Medicine''s Tissue Culture Core provides cells for research use within the department, as well as for distribution to other facilities. The core obtains hMSCs from bone marrow donor samples and expands these cells for research use. The hMSC''s are also characterized for bone, fat and cartilage differentiation, and are stored on site for use. The Tissue Culture Core also handles the expansion and characterization of mouse and rat MSC''s. The animal cells are cultured in a separate area, and never interact with human derived cells. We also have a supply of hMSC''s marked with GFP+, Mito Red and Mito Blue available.

Proper citation: Tulane Stem Cell Research and Regenerative Medicine Tissue Culture Core (RRID:SCR_007342) Copy   

•   Source: SciCrunch Registry

http://ccr.coriell.org/Sections/Collections/CSCB/Default.aspx

Biospecimen repository that provides scientists with the opportunity to bank their pluripotent stem cell lines and develops in-house induced pluripotent stem cell (iPSC) lines for distribution. They have developed core capabilities to maintain, characterize, bank, and distribute important stem cell resources. The SCB performs extensive identification and characterization testing for all submitted human induced pluripotent stem cell (iPSC) and mouse embryonic stem cell (mES) lines. The identification and quality control measures include karyotype analysis, microsatellite analysis for parental cell line identity matching, sterility testing, and assessment of viability after cryopreservation. Pluripotency characterizations performed by SCB vary depending upon the distributing repository. * NIGMS iPSCs: Surface antigen expression, Embryoid body formation, Pluritest Gene Expression assay * NINDS iPSCs: Surface antigen expression, Embryoid body formation * NIA mES: Surface antigen expression, Embryoid body formation, Transgene induction Each characterized human iPSC line and mES line released for distribution is provided with a Certificate of Analysis, which includes information regarding characterization and quality of the line, images and links to original publications. The human iPSCs distributed by Coriell are strictly for research purposes and cannot be used in human subjects. All terms described in the Material Transfer Agreement (NIGMS and NINDS Repositories) or Assurance Form (NIA Repository) for the stem cell line must be agreed to prior to using stem cell lines from Coriell.

Proper citation: Coriell Institute Stem Cell Biobank (RRID:SCR_008745) Copy   

•   Source: SciCrunch Registry

http://narayanahospitals.com/cellsofhope/

Narayana Hrudayalaya Tissue Bank and Stem Cell Research Center (NHTB-SCRC) is a joint venture between Rotary Bangalore Health City (RBHC) and Narayana Hrudayalaya. Our mission is to create awareness on Cord Blood Banking among the masses. Our vision is to make sure that every pregnant mother in India is able to afford to bank her child''s cord blood and cord tissue in a novel form of ������??Biological Insurance������??. The center would also assist in research and development of newer stem cell therapies. These goals are met while ensuring patient safety and well being by maintaining compliance with ICMR guidelines, Good Manufacturing Practice (GMP) guidelines, strict confidentiality and adherence to ethical standards. The private cord blood bank would store cord-blood and cord tissue derived stem cells for the exclusive use of clients who would pay for the cryo-storage, for a period of 21 years. These samples would be used for the child or its siblings anytime in the future, for therapy of various medical conditions. The public cord blood bank would enable us to collect cord blood from delivery and birthing centers, process these specimens, type their HLA signature and store them in ultra-low temperature conditions for use on prospective recipients. These recipients would have to be matched against their HLA signature with the stored stem cell concentrate. Patients with a disease treatable by stem cell therapy would have to have their HLA type known and they approach us for treatment. Such patients would be matched against our library of samples to identify a suitable match which would then be issued at a nominal cost. The cost of therapy would however be separate and informed to the patient before embarking on the treatment.

Proper citation: Narayana Hrudayalaya Tissue Bank and Stem Cell Research Center (RRID:SCR_010680) Copy   

•   Source: SciCrunch Registry

http://www.biobancusa.com/

BioBancUSA is a leading biotechnology company specializing in white blood cell collection, processing, cryopreservation and storage service. BioBancUSA, a private company headquartered in Monterey, California, is the exclusive licensee of the original patent for the collection, processing and cryopreservation technology of white blood cells, giving you the assurance of both technical integrity and legal legitimacy that you can count on. BioBancUSA is dedicated to providing our clients with the highest quality immune cell preservation for their future medical use. We are committed to the most advanced technology, exceptional, personalized service and leading-edge innovation to benefit our customers, health care providers, shareholders and employees.

Proper citation: Biobanc USA (RRID:SCR_010622) Copy   

•   Source: SciCrunch Registry

http://www.rucdr.org/

RUCDR is a biobank and a service organization that maintains human blood, serum, saliva, tissue and the genetic products derived from those. Services include technical consultation and logistical support for biobanking. Researchers can order biomaterials and apply for phenotypic / genotypic data.

Proper citation: Rutgers Cell and DNA Repository (RRID:SCR_010624) Copy   

•   Source: SciCrunch Registry

http://www.ntnu.edu/hunt

International biobank storing whole blood and DNA from 200,000 individuals, serum and plasma samples from more than 100,000 individuals as well as urine, RNA tubes, cells, buffy coat and Na-heparin tubes for environmental analysis for as many as 50,000 individuals. All bio-specimens from the HUNT surveys are collected, processed and stored at the HUNT Biobank in Levanger. The National CONOR Biobank is located on the same site, where it serves as a central research repository for DNA samples from all the largest Norwegian health surveys. These make up the Cohorts of Norway (CONOR), which include samples from more than 200,000 individuals. * HUNT 1 was carried out in 1984-1986 to establish the health history of 75,000 people. * HUNT 2, carried out in 1995-1997, focused on the evolution of the health history of 74,000 people. This included blood sample collection from 65,000 people. The data that accompany biospecimens in the biobank are stored in secured computer systems that run complex database management and analysis software. * HUNT 3 was completed in June 2008. 93,210 people were invited to participate in the study, and as of the 6th of June, 2008, 48,289 people participated (52% participation rate). The data, collected by means of questionnaires, interviews, clinical examinations and collection of blood and urine samples, will be ready for analysis in January 2009. * Young-HUNT is the adolescent part of HUNT including participants aged 13-19 years. Young-HUNT1 (1995-97) was conducted as part of HUNT2, 9141 adolescents participated (90% response rate). Young-HUNT2 (2000-01) was a follow-up study of Young-HUNT1, 2400 students participated in both studies (77% of the invited). Young-HUNT3 (2006-08) was a new cross-sectional study as part of HUNT3. This time 8677 adolescents participated (87% response rate). Data collection included self-reported questionnaires, structured interviews, clinical measurements and, in Young-HUNT3, buccal smears. All institutions with research expertise can apply for access to analyze HUNT data. Projects must have recommendations from The Regional Committee for Medical Research in Norway (REK) and be registered with The Norwegian Social Science Data Services (NSD).

Proper citation: Hunt Biobank (RRID:SCR_010626) Copy   

•   Source: SciCrunch Registry

http://mayoresearch.mayo.edu/mitochondrial-disease-biobank/

A biobank of blood and tissue samples from patients with known and suspected mitochondrial diseases along with data from their families. Samples are used in research to understand the family of mitochondrial disorders such as Alpers' syndrome, encephalopathy, and Friedrieich's ataxia, among many others. The goal of the biobank is to advance the understanding of mitochondrial disease and improve patient care.

Proper citation: Mayo Mitochondrial Disease Biobank (RRID:SCR_010598) Copy   

•   Source: SciCrunch Registry

https://www.eummcr.info/

Embryonic stem cell distribution unit that distributes material arising within European Conditional Mouse Mutagenesis Program consortium, currently targeting vectors and ES cells. Upon user request EUCOMM grow targeting vectors from glycerol stocks and prepare vector DNA. Identity of vector is verified by restriction mapping. Upon user request EUCOMM thaw, expand and re-freeze several aliquots of desired ES cell clone. Standard controls include PCR based assay. Upon additional request EuMMCR unit develops genotyping PCR, which can be used to genotype chimeric mice that may be generated using those ES cell clones.

Proper citation: EuMMCR (RRID:SCR_001506) Copy   

•   Source: SciCrunch Registry

https://www.ibdgc.org/

Repository of biospecimen and phenotype data collected from Crohn's disease and ulcerative colitis cases and controls recruited at six sites throughout North America that are available to the scientific community. Phenotyping is performed using a standardized protocol, and lymphoblastoid cell lines are established for each subject. Phenotype data for each subject are collected by the Consortium's Data Coordinating Center (DCC), and phenotype data for all subjects with DNA samples are available. The resulting DNA samples have already been utilized by the Consortium to complete various association studies, including genome-wide association studies using dense genotyping arrays. Researchers can obtain DNA samples and phenotype, genotype, and pedigree data through the Data Repository. GWAS data must be requested through dbGAP. The IBDGC is involved with independent genetic research studies and actively works with members of the IBD and genetic communities on collaborative projects. They are also members of the International IBD Genetics Consortium. Phenotype Tools: The Consortium Phenotype Committee, led by Dr. Hillary Steinhart designed and validated paper forms to collect extensive phenotype data on Crohn's Disease and ulcerative colitis. Consortium phenotype tools are available for use by non-Consortium members.

Proper citation: NIDDK Inflammatory Bowel Disease Genetics Consortium (RRID:SCR_001461) Copy   

•   Source: SciCrunch Registry